GlassScriptPhysician profile
Alison Vukich
NPI 1245282482
$8,026.23
in general payments reported to CMS, 2019-2025
43 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $901 · 2021: $1,092 · 2022: $1,110 · 2023: $1,316 · 2024: $1,351 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,023.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $697.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $597.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $595.66 | 2019-2025 | |
| Abbvie INC. | $512.65 | 2021-2025 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.14 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $447.62 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $335.89 | 2020-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $325.74 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $306.51 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $301.20 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Abbott Laboratories | $222.00 | 2023-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $220.88 | 2019-2025 | Zoryve, Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $207.97 | 2019-2022 | |
| Vivus LLC | $193.00 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Vukich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.